undamentalytics Newsletter
Sign in

Neogenomics Inc income statement

In fiscal 2025, Neogenomics Inc reported revenue of $727m, up 10.1% on the year before, operating income of −$116m (a -15.9% margin) and net income of −$108m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue232240277409444484510592661727788
Cost of revenue134138149212259297322347370413435
Gross profit98102127197186187188245290314353
Research and development54388223027313739
Selling and marketing24242947486367718592102
General and administrative647085128144221243243260273260
Operating income231013−14−119−158−108−92−116−49
Interest expense—6647887743
Net interest income106—————————
Income before tax−8−344−14−15−159−97−81−110−36
Income tax−2−21−4−18−7−15−9−2−2−4
Net income−6−0384−8−144−88−79−108−32
Diluted EPS——————————−$0.25
Diluted shares (average)78m79m92m104m112m120m124m126m127m128m129m
EBITDA1818263312−89−122−70−53−80−15

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: NEO vs RGENNEO vs TXGAZTA vs NEONEO vs TECH

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Neogenomics Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Neogenomics Inc.